Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy?
Infectious disease could fuel Eli Lilly's next growth phase.
Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy?
Overview
For the past several years, the market has associated Eli Lilly (NYSE: LLY) with one thing: obesity. Its blockbuster weight-loss drug Zepbound and diabetes treatment Mounjaro have transformed the company, helping drive annual revenue from $34.1 billion in 2023 to more than $65.2 billion in 2025.
But it would be foolish to ignore the elephant in the room: What's next after GLP-1 and obesity treatments? Lilly may have just provided part of the answer.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
- 51% of U.S. adults say the American Dream is out of reach for most people right now: CNBC survey
- A massive 16% market swing just rocked South Korea over 24 hours. The retail ‘ants’ holding the wheel are driving dangerously.
- I’m 60, retired with $3 million. My fiancée, 55, has $1 million but plans to work for the next 10 years. Are we compatible?
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
